[go: up one dir, main page]

MX2024010625A - Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos. - Google Patents

Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.

Info

Publication number
MX2024010625A
MX2024010625A MX2024010625A MX2024010625A MX2024010625A MX 2024010625 A MX2024010625 A MX 2024010625A MX 2024010625 A MX2024010625 A MX 2024010625A MX 2024010625 A MX2024010625 A MX 2024010625A MX 2024010625 A MX2024010625 A MX 2024010625A
Authority
MX
Mexico
Prior art keywords
same
manufacturing
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
MX2024010625A
Other languages
English (en)
Inventor
Vincent Gerusz
Vasileios Tatsis
Mihiro Sunose
Juan Bravo
Terry Finn
Danig Pohin
Pierre-Michel Regenass
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2024010625A publication Critical patent/MX2024010625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos de la estructura general (ver Fórmula) que son adecuados como compuestos antibióticos para el tratamiento de infecciones por N. gonorrhoeae e infecciones relacionadas.
MX2024010625A 2018-11-12 2021-05-11 Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos. MX2024010625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205619 2018-11-12
EP18213016 2018-12-17

Publications (1)

Publication Number Publication Date
MX2024010625A true MX2024010625A (es) 2024-09-05

Family

ID=68610175

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021005535A MX2021005535A (es) 2018-11-12 2019-11-11 Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos.
MX2024010625A MX2024010625A (es) 2018-11-12 2021-05-11 Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021005535A MX2021005535A (es) 2018-11-12 2019-11-11 Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos.

Country Status (26)

Country Link
US (1) US12545672B2 (es)
EP (1) EP3880675B1 (es)
JP (1) JP2022506957A (es)
KR (1) KR102872166B1 (es)
CN (1) CN113272302B (es)
AU (1) AU2019380568B2 (es)
BR (1) BR112021009106A2 (es)
CA (1) CA3119390A1 (es)
CL (2) CL2021001244A1 (es)
DK (1) DK3880675T3 (es)
ES (1) ES3009675T3 (es)
FI (1) FI3880675T3 (es)
HU (1) HUE069513T2 (es)
IL (2) IL282950A (es)
LT (1) LT3880675T (es)
MX (2) MX2021005535A (es)
PH (1) PH12021551058A1 (es)
PL (1) PL3880675T3 (es)
RS (1) RS66257B1 (es)
SG (1) SG11202104863RA (es)
SI (1) SI3880675T1 (es)
SM (1) SMT202400519T1 (es)
TN (1) TN2021000092A1 (es)
UA (1) UA129248C2 (es)
WO (1) WO2020099341A1 (es)
ZA (1) ZA202103516B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551444A1 (en) 2019-12-19 2023-11-20 Debiopharm Int Sa Novel compounds and their use
WO2022187329A1 (en) * 2021-03-03 2022-09-09 The Board Of Trustees Of The University Of Illinois Fabi inhibitors for gram-negative pathogens
CN117881679A (zh) 2021-06-23 2024-04-12 德彪药业国际股份公司 新型化合物及其应用
WO2025073269A1 (zh) * 2023-10-07 2025-04-10 广州白云山医药集团股份有限公司白云山制药总厂 一种FabI酶抑制剂及其应用
WO2025078209A1 (en) 2023-10-09 2025-04-17 Debiopharm International S.A. Antibiotic compounds for treating bacterial infections
WO2025248051A1 (en) 2024-05-31 2025-12-04 Debiopharm International S.A. Acrylamide derivatives for the treatment of diseases associated with pathogenic bacteria in the gastrointestinal system

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
HK1049656A1 (zh) 1999-10-08 2003-05-23 Smithkline Beecham Corporation Fab i抑制剂
US7049310B2 (en) * 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
DE602004016831D1 (de) * 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
EP2758376A4 (en) 2011-09-19 2015-04-29 Vitas Pharma Res Private Ltd HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS
WO2013080222A1 (en) 2011-12-02 2013-06-06 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors
HRP20190980T1 (hr) * 2012-06-19 2019-08-23 Debiopharm International Sa Derivati predlijeka (e)-n-metil-n((3-metilbenzofuran-2 il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
WO2014023814A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
US9951056B2 (en) 2013-09-30 2018-04-24 Beijing Innocare Pharma Tech Co., Ltd. Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
PH12022551444A1 (en) 2019-12-19 2023-11-20 Debiopharm Int Sa Novel compounds and their use

Also Published As

Publication number Publication date
SI3880675T1 (sl) 2025-02-28
BR112021009106A2 (pt) 2021-08-10
MX2021005535A (es) 2021-09-08
CN113272302A (zh) 2021-08-17
IL311894B1 (en) 2026-02-01
RS66257B1 (sr) 2024-12-31
US20230035837A1 (en) 2023-02-02
FI3880675T3 (fi) 2024-12-09
SMT202400519T1 (it) 2025-01-14
KR20210093292A (ko) 2021-07-27
IL282950A (en) 2021-06-30
CA3119390A1 (en) 2020-05-22
CL2021001244A1 (es) 2021-11-19
US12545672B2 (en) 2026-02-10
LT3880675T (lt) 2024-12-27
IL311894A (en) 2024-06-01
SG11202104863RA (en) 2021-06-29
PH12021551058A1 (en) 2021-11-22
ES3009675T3 (en) 2025-03-31
WO2020099341A1 (en) 2020-05-22
HUE069513T2 (hu) 2025-03-28
EP3880675B1 (en) 2024-11-06
NZ776487A (en) 2024-10-25
TN2021000092A1 (en) 2023-01-05
AU2019380568A1 (en) 2021-06-17
CL2022003703A1 (es) 2023-06-09
JP2022506957A (ja) 2022-01-17
KR102872166B1 (ko) 2025-10-15
PL3880675T3 (pl) 2025-02-10
AU2019380568B2 (en) 2024-08-15
ZA202103516B (en) 2025-11-26
DK3880675T3 (da) 2024-12-02
UA129248C2 (uk) 2025-02-26
EP3880675A1 (en) 2021-09-22
CN113272302B (zh) 2024-08-13

Similar Documents

Publication Publication Date Title
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
PH12021500014A1 (en) Fused ring compounds
WO2020160193A3 (en) Compounds and uses thereof
EP4483881A3 (en) Fused ring compounds
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2023002507A (es) Inhibidores de cd73.
EP4360651A3 (en) Glp-1 compositions and uses thereof
ZA202204941B (en) Cd73 inhibitors
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
ZA202309446B (en) Rapamycin analogs and uses thereof
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
WO2018187623A8 (en) Crystalline forms of (s)-afoxolaner
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
AU2018320416A8 (en) Pyridylpyridone compounds
WO2020049598A3 (en) Apalutamide polymorphs
AU2018320419A1 (en) Morpholinylpyridone compounds
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
PH12021550320A1 (en) Bicyclic heteroaryl derivatives
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение
WO2019157225A3 (en) Certain chemical entities, compositions, and methods
MX2022004639A (es) Compuestos biciclicos que contienen nitrogeno.
EA202091327A1 (ru) Макроциклические соединения для лечения заболеваний